Compare Cassava Sciences Inc (FLNA) vs Lululemon Athletica Inc (LULU) Price & Performance

FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.

While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.

Lululemon stock trades at $94.5, down 54% year-to-date and near its 52-week low, reflecting a bearish technical trend. Despite strong profitability with a 12.78% net income margin and a low P/E of 7.63, the stock faces headwinds from recent revenue declines and multiple securities fraud investigations. Earnings have beaten estimates in recent quarters, but negative sentiment and governance concerns weigh on investor confidence.

The outlook remains cautious; the stock's deep discount to historical valuations presents a potential opportunity, but risks from legal probes, competitive pressures, and weak growth visibility suggest limited near-term upside. Analyst consensus is mixed with a $97.67 price target, indicating modest potential from current levels amid high uncertainty.